N/A
Completed N=67
Liver Cancer Community Education
Source: ClinicalTrials.gov NCT04272619 ↗Enrolled (actual)
67
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcomePrimary: Change in Mean Liver Cancer Knowledge — 1.26 score on a scale
Summary
This study proposes to bridge the gap between evidence and action and combat rising liver cancer rates attributed to Hepatitis B and C infection in Philadelphia by identifying neighborhoods with higher than expected rates of liver cancer and related risk factors and administering an educational intervention about liver cancer and neighborhood health in those communities, working with existing community partners at Fox Chase Cancer Center.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Mean Liver Cancer Knowledge |
1.26 | — |
| PRIMARY Change in General Interest in Learning About Neighborhood Health |
-1.81 | — |
| PRIMARY Change in Interest in Learning About Neighborhood Health From a Healthcare Provider |
-0.95 | — |
| PRIMARY Change in Interest in Learning About Neighborhood Health From Other Sources |
-0.90 | — |
| PRIMARY Change in Interest in Discussing High Liver Cancer Risk With a Healthcare Provider |
-1.58 | — |
| PRIMARY Change in Outcome Expectancies for Learning About Neighborhood Health - Patient Behavior |
0.83 | — |
| PRIMARY Change in Outcome Expectancies for Learning About Neighborhood Health - Provider Behavior |
-0.77 | — |
| PRIMARY Change in Intentions About Communicating With Healthcare Provider - Neighborhood Prevalence of Liver Cancer |
0.79 | — |
| PRIMARY Change in Intentions About Communicating With Healthcare Provider - Liver Cancer Screening |
0.67 | — |
| PRIMARY Change in Intentions About Communicating With Healthcare Provider - Liver Cancer Risk |
0.35 | — |
Eligibility Criteria
Inclusion Criteria
- Speaks/reads English
- Lives in Philadelphia or receives healthcare at a community partner site in Philadelphia
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT04272619). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.